The reiteration of a Buy rating and maintenance of a $107 price target by a reputable analyst like Mike Matson from Needham is likely to instill confidence among investors and could positively influence Conmed's stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.